Utrogestan (progesterone) / Besins Healthcare 
Welcome,         Profile    Billing    Logout  
 0 Diseases   13 Trials   13 Trials   55 News 


123»
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  Natural Progesterone for the Treatment of Recurrent Glioblastoma (clinicaltrials.gov) -  Jun 11, 2024   
    P1,  N=32, Recruiting, 
    Recruiting --> Active, not recruiting | N=522 --> 362 Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Enrollment closed, Trial completion date, Trial primary completion date:  Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor (clinicaltrials.gov) -  Nov 8, 2022   
    P4,  N=140, Active, not recruiting, 
    However, the relationship between serum progesterone and the probability of live birth appears to be non-linear in women receiving exclusively subcutaneous progesterone, suggesting that in this subgroup of women, high serum progesterone may also be detrimental to treatment success. Unknown status --> Active, not recruiting | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Jun 2021 --> Jan 2023
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    To determine the pre-test probability of malignancy for women bleeding on “New” HRT – Are we over or under-investigating? () -  Oct 23, 2022 - Abstract #ESGE2022ESGE_1042;    
    Women on Utrogestan are over-represented in referrals made before 3 and 6 months after commencing HRT adding further pressure to already overstretched waiting lists and clinician anxiety. Large studies are needed to establish the prevalence of bleeding with Utrogestan for endometrial protection, the pre-test probability of malignant disease and the risk of invasive investigation compared with alternatives.
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    New trial:  GnRH Agonist for Luteal Phase Support. (clinicaltrials.gov) -  Aug 2, 2022   
    P=N/A,  N=150, Active, not recruiting, 
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy (clinicaltrials.gov) -  Apr 20, 2022   
    P=N/A,  N=300, Not yet recruiting, 
    The positive changes in traditional markers were not reflected in the cardiogenic biomarker, cfPWV, which has demonstrated a higher positive predictive value for cardiovascular events than traditional measurements. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial initiation date:  Natural Progesterone for the Treatment of Recurrent Glioblastoma (clinicaltrials.gov) -  Apr 18, 2022   
    P1,  N=32, Recruiting, 
    Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025 Initiation date: Aug 2021 --> Apr 2022
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  P4&REE: Progesterone and Resting Energy Expenditure (clinicaltrials.gov) -  Mar 31, 2022   
    P4,  N=2, Terminated, 
    Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 N=23 --> 2 | Trial completion date: Dec 2022 --> May 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> May 2021; massive recruitment problems became apparent because of the strict inclusion criteria of our study.
  • ||||||||||  Utrogestan (progesterone) / Besins healthcare
    [VIRTUAL] Do pregnancy rates vary using different luteal support regimes in frozen embryo transfer cycles? () -  Jul 23, 2021 - Abstract #Fertility2021Fertility_131;    
    Results with single daily subcutaneous progesterone injections were disappointing, albeit cycle numbers were low compared to the other medicated protocols. When compared with a standard vaginal progesterone only regime; the combination of a daily morning subcutaneous progesterone injections with an evening dose of vaginal progesterone, was found to significantly increase clinical pregnancy rates by 58%.
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy (clinicaltrials.gov) -  Mar 11, 2021   
    P=N/A,  N=300, Not yet recruiting, 
    When compared with a standard vaginal progesterone only regime; the combination of a daily morning subcutaneous progesterone injections with an evening dose of vaginal progesterone, was found to significantly increase clinical pregnancy rates by 58%. Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Oct 2021 --> Dec 2022
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Enrollment change, Trial withdrawal:  POPPET: Vaginal Progesterone for the Prevention of Preterm Birth in Twins (clinicaltrials.gov) -  Jan 28, 2021   
    P3,  N=0, Withdrawn, 
    Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Sep 2020 --> Sep 2021 N=300 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  P4&REE: Progesterone and Resting Energy Expenditure (clinicaltrials.gov) -  Dec 21, 2020   
    P4,  N=23, Recruiting, 
    Utrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes. Trial primary completion date: Mar 2021 --> Dec 2022 | Trial completion date: Aug 2021 --> Dec 2022
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial initiation date, Trial primary completion date:  Comparison Between Vaginal Pessary and Progestogen in Twin Pregnancy With Short Cervical Length (clinicaltrials.gov) -  Nov 19, 2020   
    P3,  N=310, Not yet recruiting, 
    Recruiting --> Completed | N=20 --> 30 | Trial completion date: Dec 2020 --> Aug 2020 Trial completion date: Jul 2022 --> Jan 2023 | Initiation date: Jul 2020 --> Jan 2021 | Trial primary completion date: Apr 2022 --> Jan 2023
  • ||||||||||  Utrogestan (progesterone) / Besins healthcare
    Journal:  Melanonychia Striata: Nail Alterations during Pregnancy. (Pubmed Central) -  Aug 20, 2020   
    She was otherwise healthy and had no previous pigmentation disorders, chronic diseases, or any other pregnancy complications. There was no family history of pigmentation disorders.
  • ||||||||||  Utrogestan (progesterone) / Besins Healthcare
    Trial completion date, Trial primary completion date:  Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy (clinicaltrials.gov) -  Mar 4, 2020   
    P=N/A,  N=300, Not yet recruiting, 
    PPOS protocol using medroxyprogesterone acetate or utrogestan was comparable in terms of oocytes and pregnancy outcome, whereas the administration of utrogestan may result in an improved blastulation than medroxyprogesterone acetate, which needs further exploration. Trial completion date: Dec 2020 --> Oct 2022 | Trial primary completion date: Dec 2019 --> Oct 2021